Skip to content

Can high-flow oxygen enhance oxygenation during exercise by optimizing the benefits of Pulmonary Rehabilitation in patients with Diffuse Interstitial Lung Disease (ILD) with oxygen desaturation during effort?

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-519541-30-00
Acronym
IIBSP-OXI-2017-18
Enrollment
60
Registered
2024-11-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ILD

Brief summary

The primary endpoint will be the average SpO₂ achieved throughout the entire training period, comparing both groups.

Detailed description

Dyspnea during daily life activities (mMRC scale, dyspnea domain of the CRQ), Dyspnea during exertion before and after the 6-minute walk test (6MWT) (Borg scale), Exercise capacity measured by the 6MWT without oxygen support, Health-Related Quality of Life (HRQoL) assessed using the KBILD and SF36 questionnaires, Full pulmonary function test (spirometry, lung volumes, diffusion, and blood gases), Adverse effects of the program, Adverse events, Program adherence

Interventions

DRUGgas medicinal comprimido
DRUGConoxia 100% medicinal gas
DRUGcryogenic

Sponsors

Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The primary endpoint will be the average SpO₂ achieved throughout the entire training period, comparing both groups.

Secondary

MeasureTime frame
Dyspnea during daily life activities (mMRC scale, dyspnea domain of the CRQ), Dyspnea during exertion before and after the 6-minute walk test (6MWT) (Borg scale), Exercise capacity measured by the 6MWT without oxygen support, Health-Related Quality of Life (HRQoL) assessed using the KBILD and SF36 questionnaires, Full pulmonary function test (spirometry, lung volumes, diffusion, and blood gases), Adverse effects of the program, Adverse events, Program adherence

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026